Factor XIII, Functional

You can bleed for hours after a small injury, form deep bruises from little trauma, or lose pregnancies again and again, and still have a standard clotting panel that reads normal. Factor XIII deficiency is one of the specific problems those routine tests miss.

Standard tests check whether a clot forms. This test checks whether the clot holds. Those are different questions, and some rare but treatable bleeding disorders hide in the gap.

What Factor XIII Does

Factor XIII (FXIII), also called fibrin stabilizing factor, is the enzyme that finishes the job every other clotting factor starts. When you cut yourself, a cascade of proteins builds a soft fibrin mesh over the wound. Factor XIII then stitches that mesh together with strong chemical links, turning a fragile plug into a tougher clot that resists stress and early breakdown.

It belongs to a family of enzymes called transglutaminases. These enzymes join protein strands together. Factor XIII also locks alpha-2-antiplasmin onto the clot. Alpha-2-antiplasmin is one of the body's brakes on clot breakdown. Without enough Factor XIII activity, clots can still form on schedule but come apart too soon, which is why bleeding may start hours after an injury rather than right away.

This is the functional, or activity, version of the test, usually measured in platelet-poor plasma from a blood draw. It checks how well the enzyme works, not just how much Factor XIII protein is present. That distinction matters, because a person can have a normal amount of protein that does not work properly.

Why a Normal Clotting Panel Misses It

The usual clotting tests, prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT), all measure the moment a clot first appears. In a Factor XIII problem that moment arrives right on time, so those tests usually read normal. The defect is in clot quality, not clot formation.

That explains why the diagnosis can be missed for years. The older clot solubility screen only catches severe deficiency and can miss mild or moderate reductions. A quantitative activity assay is the better clinical test when the story fits Factor XIII deficiency.

It should not be used as a broad answer for every unexplained bruise. In one recent study of people with bleeding of unknown cause, truly meaningful Factor XIII deficiency was uncommon. The test earns its place when the pattern is specific: delayed bleeding, poor wound closure, recurrent pregnancy loss, a family history, or bleeding that standard tests cannot explain.

Inherited Deficiency

Congenital Factor XIII deficiency is rare, around 1 in 2 million, and usually happens when a child inherits disease-causing variants from both parents. It is more common in communities where relatives marry. The presentation is distinctive: bleeding from the umbilical stump in about 80% of affected newborns, bleeding into the brain in about a quarter to a third of untreated cases, and repeated miscarriage in affected women.

How far the activity falls changes the stakes sharply. Very low activity is the danger zone for spontaneous major bleeding. Milder reductions may still matter under stress, especially surgery, trauma, or childbirth.

If you or a child has bleeding that does not fit a normal clotting panel, this test can uncover a diagnosis that is treatable. That matters most in the severe inherited form, where early treatment can prevent the brain bleeds that cause the most harm.

Acquired Deficiency

You do not have to be born with a Factor XIII problem to develop one. The acquired form shows up in major trauma, big operations, severe burns, liver disease, inflammatory bowel disease, and people on ECMO. ECMO is machine-supported heart or lung support. Factor XIII can also fall when autoantibodies attack it directly. Autoantibodies are immune proteins aimed at one of your own proteins.

After serious injury, Factor XIII can keep falling for days. In trauma patients, activity fell from about 85% to about 58% of normal over the first week, a drop of about a third. During ECMO, most adults in a prospective study developed acquired deficiency.

The consequences are concrete. In a study of 876 brain-surgery patients, people whose Factor XIII fell into a low postoperative range had about six times the risk of bleeding into the surgical site, and about twelve times the risk when fibrinogen was also low. In advanced liver disease, marked Factor XIII deficiency has been tied to severe upper gut bleeding and higher death rates. In cirrhosis patients who also had acute kidney injury, activity ran about a third lower than in those without kidney injury.

A low reading during a hospital stay or serious illness usually reflects that crisis, not your stable baseline. The value is real and may matter in the moment, but it should be repeated after recovery before anyone treats it as a lasting deficiency.

Bleeding Around Pregnancy and Delivery

Factor XIII helps hold a pregnancy, and severe inherited deficiency is linked to repeated miscarriage. It also appears to shape bleeding at delivery. In women giving birth, the activity level measured before birth tracked closely with the amount of Factor XIII A-subunit protein present, a correlation of 0.89 where 1.0 would be a perfect match. Higher pre-birth activity has also been linked to less measured blood loss after delivery.

A common assumption is backwards: Factor XIII does not reliably rise through pregnancy. Several studies show a fall during normal pregnancy instead. For a woman with unexplained recurrent loss, this enzyme is a specific thing to check, not a reason to stop looking.

The Other Direction: Clots That Resist Breakdown

A high level is a different problem. Studies measuring Factor XIII subunits and activity in healthy adults found that A-subunit protein was higher with older age, female sex, and smoking. That is a related protein measure, not the same thing as the plasma activity this test reports, but the two tend to track together.

Researchers care because Factor XIII helps make clots more stable and harder to break down. In heart attack and ischemic stroke, part of the harm comes from a clot that blocks blood flow and resists clearance. For most people, the low end is the actionable end because that is where bleeding lives. The high end is still mostly a research signal rather than a number to treat on its own.

When Results Can Be Misleading

• Acute illness and consumption: sepsis, disseminated intravascular clotting, major trauma, burns, surgery, and ECMO can all pull Factor XIII down quickly. In disseminated intravascular clotting, clotting proteins are used up throughout the body. A value drawn during any of these reflects the crisis, not your baseline.
• Kidney and liver trouble: liver disease can lower production, and acute kidney injury can drop the level further. In cirrhosis with kidney injury, activity ran about a third lower than in cirrhosis without it.
• Certain drugs: valproate and tocilizumab have both been linked to acquired low Factor XIII. This is a real biological drop, not a lab artifact, so unusual bruising or delayed bleeding on either drug deserves attention.
• Recent blood products or replacement: plasma, cryoprecipitate, and Factor XIII concentrate can temporarily raise the result and make an underlying deficiency harder to see.
• Sample handling: the activity assay is usually run on platelet-poor plasma. Poor processing, delayed freezing, or platelet contamination can make results harder to interpret.
• Assay method: the old clot solubility screen only catches severe deficiency and may call milder cases normal. Make sure a quantitative activity assay was used.